Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel Free MBX Stock Alerts

Microbix Biosystems (MBX) Competitors

Microbix Biosystems logo
C$0.30 0.00 (0.00%)
As of 03:57 PM Eastern
Compare

MBX vs. AKU, GEN, LMD, LXG, and SQD

Should you buy Microbix Biosystems stock or one of its competitors? Microbix Biosystems's main competitors and comparable companies include Akumin (AKU), GeneNews (GEN), LED Medical Diagnostics (LMD), LexaGene (LXG), and SQI Diagnostics (SQD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Microbix Biosystems compare to Akumin?

Akumin (TSE:AKU) and Microbix Biosystems (TSE:MBX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

Akumin has a net margin of -34.67% compared to Microbix Biosystems' net margin of -38.62%. Microbix Biosystems' return on equity of -21.02% beat Akumin's return on equity.

Company Net Margins Return on Equity Return on Assets
Akumin-34.67% -483.86% 0.47%
Microbix Biosystems -38.62%-21.02%3.82%

30.3% of Akumin shares are owned by institutional investors. Comparatively, 0.2% of Microbix Biosystems shares are owned by institutional investors. 33.0% of Akumin shares are owned by company insiders. Comparatively, 14.0% of Microbix Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Microbix Biosystems had 2 more articles in the media than Akumin. MarketBeat recorded 2 mentions for Microbix Biosystems and 0 mentions for Akumin. Akumin's average media sentiment score of 0.00 beat Microbix Biosystems' score of -0.14 indicating that Akumin is being referred to more favorably in the media.

Company Overall Sentiment
Akumin Neutral
Microbix Biosystems Neutral

Akumin has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market. Comparatively, Microbix Biosystems has a beta of 0.719241, meaning that its stock price is 28% less volatile than the broader market.

Microbix Biosystems has lower revenue, but higher earnings than Akumin. Microbix Biosystems is trading at a lower price-to-earnings ratio than Akumin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AkuminC$737.69M0.00-C$255.80M-C$3.80N/A
Microbix BiosystemsC$14.81M2.78C$3.39M-C$0.04N/A

Summary

Akumin and Microbix Biosystems tied by winning 6 of the 12 factors compared between the two stocks.

How does Microbix Biosystems compare to GeneNews?

Microbix Biosystems (TSE:MBX) and GeneNews (TSE:GEN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

0.2% of Microbix Biosystems shares are owned by institutional investors. 14.0% of Microbix Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Microbix Biosystems has higher revenue and earnings than GeneNews. Microbix Biosystems is trading at a lower price-to-earnings ratio than GeneNews, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbix BiosystemsC$14.81M2.78C$3.39M-C$0.04N/A
GeneNewsC$234.59K0.00-C$11.56M-C$0.07N/A

GeneNews has a net margin of 0.00% compared to Microbix Biosystems' net margin of -38.62%. GeneNews' return on equity of 0.00% beat Microbix Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
Microbix Biosystems-38.62% -21.02% 3.82%
GeneNews N/A N/A N/A

In the previous week, Microbix Biosystems had 2 more articles in the media than GeneNews. MarketBeat recorded 2 mentions for Microbix Biosystems and 0 mentions for GeneNews. GeneNews' average media sentiment score of 0.00 beat Microbix Biosystems' score of -0.14 indicating that GeneNews is being referred to more favorably in the news media.

Company Overall Sentiment
Microbix Biosystems Neutral
GeneNews Neutral

Summary

Microbix Biosystems beats GeneNews on 7 of the 11 factors compared between the two stocks.

How does Microbix Biosystems compare to LED Medical Diagnostics?

LED Medical Diagnostics (CVE:LMD) and Microbix Biosystems (TSE:MBX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Microbix Biosystems has lower revenue, but higher earnings than LED Medical Diagnostics. LED Medical Diagnostics is trading at a lower price-to-earnings ratio than Microbix Biosystems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LED Medical DiagnosticsC$14.96M1.04-C$1.51M-C$0.04N/A
Microbix BiosystemsC$14.81M2.78C$3.39M-C$0.04N/A

0.2% of Microbix Biosystems shares are owned by institutional investors. 14.0% of Microbix Biosystems shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

LED Medical Diagnostics has a net margin of 0.00% compared to Microbix Biosystems' net margin of -38.62%. LED Medical Diagnostics' return on equity of 0.00% beat Microbix Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
LED Medical DiagnosticsN/A N/A N/A
Microbix Biosystems -38.62%-21.02%3.82%

In the previous week, Microbix Biosystems had 2 more articles in the media than LED Medical Diagnostics. MarketBeat recorded 2 mentions for Microbix Biosystems and 0 mentions for LED Medical Diagnostics. LED Medical Diagnostics' average media sentiment score of 0.00 beat Microbix Biosystems' score of -0.14 indicating that LED Medical Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
LED Medical Diagnostics Neutral
Microbix Biosystems Neutral

Summary

Microbix Biosystems beats LED Medical Diagnostics on 7 of the 12 factors compared between the two stocks.

How does Microbix Biosystems compare to LexaGene?

Microbix Biosystems (TSE:MBX) and LexaGene (CVE:LXG) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Microbix Biosystems has higher revenue and earnings than LexaGene. Microbix Biosystems is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbix BiosystemsC$14.81M2.78C$3.39M-C$0.04N/A
LexaGeneC$110.93K133.13-C$8.54M-C$0.08N/A

0.2% of Microbix Biosystems shares are held by institutional investors. Comparatively, 0.1% of LexaGene shares are held by institutional investors. 14.0% of Microbix Biosystems shares are held by company insiders. Comparatively, 17.9% of LexaGene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

LexaGene has a net margin of 0.00% compared to Microbix Biosystems' net margin of -38.62%. Microbix Biosystems' return on equity of -21.02% beat LexaGene's return on equity.

Company Net Margins Return on Equity Return on Assets
Microbix Biosystems-38.62% -21.02% 3.82%
LexaGene N/A -339.54%-120.21%

In the previous week, Microbix Biosystems had 2 more articles in the media than LexaGene. MarketBeat recorded 2 mentions for Microbix Biosystems and 0 mentions for LexaGene. LexaGene's average media sentiment score of 0.00 beat Microbix Biosystems' score of -0.14 indicating that LexaGene is being referred to more favorably in the news media.

Company Overall Sentiment
Microbix Biosystems Neutral
LexaGene Neutral

Microbix Biosystems has a beta of 0.719241, suggesting that its stock price is 28% less volatile than the broader market. Comparatively, LexaGene has a beta of 2.26, suggesting that its stock price is 126% more volatile than the broader market.

Summary

Microbix Biosystems beats LexaGene on 7 of the 13 factors compared between the two stocks.

How does Microbix Biosystems compare to SQI Diagnostics?

Microbix Biosystems (TSE:MBX) and SQI Diagnostics (CVE:SQD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Microbix Biosystems has a beta of 0.719241, meaning that its share price is 28% less volatile than the broader market. Comparatively, SQI Diagnostics has a beta of -0.21, meaning that its share price is 121% less volatile than the broader market.

Microbix Biosystems has higher revenue and earnings than SQI Diagnostics. Microbix Biosystems is trading at a lower price-to-earnings ratio than SQI Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbix BiosystemsC$14.81M2.78C$3.39M-C$0.04N/A
SQI DiagnosticsC$3.04M2.01-C$19.14M-C$0.05N/A

0.2% of Microbix Biosystems shares are held by institutional investors. Comparatively, 25.2% of SQI Diagnostics shares are held by institutional investors. 14.0% of Microbix Biosystems shares are held by insiders. Comparatively, 50.2% of SQI Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Microbix Biosystems had 2 more articles in the media than SQI Diagnostics. MarketBeat recorded 2 mentions for Microbix Biosystems and 0 mentions for SQI Diagnostics. SQI Diagnostics' average media sentiment score of 0.00 beat Microbix Biosystems' score of -0.14 indicating that SQI Diagnostics is being referred to more favorably in the news media.

Company Overall Sentiment
Microbix Biosystems Neutral
SQI Diagnostics Neutral

SQI Diagnostics has a net margin of 0.00% compared to Microbix Biosystems' net margin of -38.62%. SQI Diagnostics' return on equity of 0.00% beat Microbix Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
Microbix Biosystems-38.62% -21.02% 3.82%
SQI Diagnostics N/A N/A -74.70%

Summary

Microbix Biosystems beats SQI Diagnostics on 7 of the 13 factors compared between the two stocks.

Get Microbix Biosystems News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBX vs. The Competition

Export
MetricMicrobix BiosystemsLife Sciences Tools & Services IndustryHealthcare SectorTSE Exchange
Market CapC$41.25MC$9.66BC$7.06BC$12.54B
Dividend Yield2.30%1.45%2.57%6.20%
P/E Ratio-7.3260.32269.0630.69
Price / Sales2.78105.67592.969.75
Price / Cash4.1326.2570.4882.29
Price / Book1.6537.5012.914.60
Net IncomeC$3.39MC$56.66BC$3.45BC$299.09M
7 Day Performance3.45%0.25%1.12%0.94%
1 Month Performance-3.23%1.52%1.79%3.90%
1 Year Performance22.45%19.27%67.69%36.05%

Microbix Biosystems Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBX
Microbix Biosystems
N/AC$0.30
flat		N/A+7.1%C$41.25MC$14.81MN/AN/A
AKU
Akumin
N/AN/AN/AN/AC$37.20MC$737.69MN/A1,527
GEN
GeneNews
N/AN/AN/AN/AC$25.49MC$234.59KN/A2,700
LMD
LED Medical Diagnostics
N/AC$0.40
+∞		N/A+0.0%C$15.51MC$14.96MN/A46
LXG
LexaGene
N/AC$0.11
-19.2%		N/A+0.0%C$14.77MC$110.93KN/A41

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MBX) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...
TradeSmith | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Gold buyout deals have handed shareholders overnight gains up to 79 percent
Gold major acquisitions have repriced junior miners overnight, with past deals delivering gains from 40% to 1,...
Golden Portfolio | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel